DGAP-News: STRATEC Biomedical AG / Key word(s): Final Results
STRATEC reports substantial growth in 2016
- Sales of EUR 184.9 million (+25.9%; previous year: EUR 146.9 million)
STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) announced today the definitive results of the STRATEC Group for the financial year as of December 31, 2016 with the publication of its 2016 Annual Report. These figures, prepared in line with International Financial Reporting Standards (IFRS), have been audited and granted an unqualified audit opinion.
bps = basis points
1 2016 figure adjusted for one-off items resulting from transaction activities and related reorganization expenses
STRATEC Biomedical AG can look back on a superb 2016 financial year, in which it substantially increased its sales and earnings while also significantly strengthening its strategic position. As well as expanding its development team, a prerequisite for implementing numerous forthcoming development projects, STRATEC also accessed major new business fields through the acquisition of two companies. For the current 2017 financial year, the company expects to generate further growth. Moreover STRATEC will be proposing what will be already the thirteenth consecutive increase in its dividend for approval by the Annual General Meeting to be held on June 14, 2017.
The share of sales generated by service parts and consumables rose from 25.9% in the previous year to 29.0% in 2016. This figure incorporates for the first time sales of consumables at the Diatron Group and at STRATEC Consumables.
EBIT grew year-on-year by 20.1% to EUR 32.3 million, corresponding to an EBIT margin of 17.5%. Benefits of scale rose significantly during recent months and had a notable impact on margin, especially in the fourth quarter of 2016. Consolidated net income showed a corresponding increase of14.9% to EUR 25.4 million, while earnings per share grew by 14.4% to EUR 2.14.
The Group continued to receive numerous milestone payments for development services. These projects and the subsequent market launches will drive the growth planned for the years ahead.
These earnings figures have been adjusted to exclude one-off items resulting from transaction and restructuring activities, associated financing and tax expenses, tax effects relating to restructuring expenses, and one-off items resulting from the tax audit for the 2009 to 2013 assessment periods.
Subject to approval by the Annual General Meeting, shareholders can therefore expect to benefit from the thirteenth consecutive increase in the dividend since payment of the first dividend in 2004. STRATEC always strives to maintain its continuity-based dividend policy. As the Group continues to focus on internal and external growth opportunities, it may deviate temporarily from this approach. Such opportunities may result from larger-scale acquisitions or from the need to provide potential advance financing for major projects.
Development in personnel
To facilitate further growth through expansion, the Group enlarged production capacities at its Swiss location with an extension completed in 2016. Building work on a new development center at the Romanian location began in late 2015 and this was occupied in the second half of 2016. Diatron is also set to move into a further building in the first half of the current year.
STRATEC will in future continue to recruit qualified staff, especially in its development division.
Projects and other development work
The recent acquisitions have already impacted positively on developments in the current financial year, especially in the form of project negotiations and contract agreements.
The STRATEC platforms in development are already the object of specific negotiations with partners with regard to resultant cooperations. STRATEC sees this as providing a further key basis for its future development.
2016 Annual Report
The Annual General Meeting of STRATEC Biomedical AG will be held in Pforzheim on June 14, 2017. The invitation to the Annual General Meeting will be sent to shareholders in good time ahead of the meeting.
Conference call and audio webcast
The access information (telephone number, password + individual PIN) will be provided following brief registration at the following link: www.stratec.com/registration
The call may also be followed as an audio webcast at www.stratec.com/audiowebcast20170420 (brief registration required). Please note that it is not possible to submit any questions via the audio webcast. You can also follow and/or download the slide presentation via this link.
The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.
Further information can be obtained from:
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|